Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04252339
Other study ID # GO43242
Secondary ID REFMAL 678
Status Completed
Phase Phase 1
First received
Last updated
Start date February 4, 2020
Est. completion date November 22, 2022

Study information

Verified date January 2023
Source Hoffmann-La Roche
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a multi-center, open-label, dose escalation and expansion study of RLY-1971 in subjects with advanced or metastatic solid tumors.


Description:

Dose escalation/dose expansion study to assess the MTD, safety, tolerability, PK and preliminary anti-tumor activity of RLY-1971. Approximately 70 patients


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date November 22, 2022
Est. primary completion date November 22, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Subject is willing and able to provide written informed consent for the study prior to the performance of any study-specific procedures Subject is a male or female subject =18 years of age at the time of consent Subject must have an ECOG PS = 1 Subject must have histologically or cytologically confirmed advanced or metastatic solid tumor Subjects who are refractory to FDA-approved, standard therapy or for which standard or curative therapy does not exist or is not considered sufficient or appropriate by the patient or Investigator Subject must have radiographically measurable or evaluable disease Subject must have recovered from the reversible effects of prior anti-neoplastic therapy, except for alopecia and = grade 2 neuropathy. Subject has adequate end organ function Subject is willing to comply with all protocol-required visits, assessments, and procedures Male and female subjects of child-bearing potential are willing to use medically acceptable methods of birth control from the screening visit through 30 days after the last dose of study medication Exclusion Criteria: Subjects with documented history of tumor mutations that may not be amenable to treatment with RLY-1971, including: KRAS mutations: G12D, G12V, G13X, and Q61X BRAF V600E mutation MEK mutations Subjects with prior antineoplastic therapy within 3 weeks of Study Day 1, or 5 half-lives, whichever is shorter Subjects with prior palliative radiotherapy within 1 week of Study Day 1 Subjects who have had major surgery or trauma, or incomplete recovery from surgery or trauma, within 4 weeks of Study Day 1 Subjects with known central nervous system (CNS) metastases or primary CNS tumor that is associated with progressive neurologic symptoms or requires increasing doses of corticosteroids to control the CNS disease. If patient requires corticosteroids for management of CNS disease, the dose must have been stable for the 2 weeks preceding C1D1, or subject has new lesions appearing on follow up brain MRI that require CNS-directed intervention. Subjects with a history or evidence of ophthalmic disease Subjects with a history or evidence of significant cardiac dysfunction Subjects with a history or evidence of significant gastrointestinal disease Subjects with other serious concurrent medical conditions Subject is pregnant, as documented by a serum beta human chorionic gonadotropin (ß-hCG) pregnancy test consistent with pregnancy obtained within 7 days before the first dose of study treatment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RLY-1971
RLY-1971 is an oral inhibitor of SHP2.

Locations

Country Name City State
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Dana Farber Cancer Institute Boston Massachusetts
United States Massachusetts General Hospital Cancer Center Boston Massachusetts
United States Florida Cancer Specialist-Lake Mary Lake Mary Florida
United States Tennessee Oncology; Sarah Cannon Research Institute Nashville Tennessee
United States Florida Cancer Specialists - Sarasota Sarasota Florida

Sponsors (1)

Lead Sponsor Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in phospho-ERK levels Blood will be collected at pre-dose at baseline on Cycle 1, Day 1 (C1D1) and at 3 time points (pre-dose, 2 hours post-dose, and 4 hours post-dose) on Cycle 1, Day 15 (C1D15) to assess the extent of target engagement At the beginning of Cycle 1 Day 1 post and predose (Cycle = 21 days)
Other Tumor mutations by sequencing circulating tumor DNA (ctDNA) Blood will be collected at screening and at End of Treatment on all patients At the beginning of Cycle 1 Day 1
Other Duration of Response (DOR) DOR is defined as the time from the participant's initial objective response (CR or PR) to RLY-1971, to disease progression or death due to any cause, whichever occurs first Through study completion (an average of one year)
Other Progression-free Survival (PFS) PFS is defined as the time from the start of study treatment to the first documented disease progression per RECIST v1.1, or death due to any cause, whichever occurs first Through study completion (an average of one year)
Primary Maximum Tolerated Dose (MTD) MTD is defined as a dose level immediately below that at which =2 of 6 subjects experience a DLT during the first cycle. Escalation Phase - 18 month Enrollment
Primary Recommended Phase 2 Dose (RP2D) RP2D may be the same dose level or lower than the determined MTD. Escalation Phase - 18 month Enrollment
Secondary Plasma concentration levels of RLY-1971 Blood samples may be taken at pre-dose, 0.5, 1, 2, 4, 6, and 8hrs on Cycle 1 Day 1 and 15, 24 hrs post dose on Cycle 1 Day 2, and pre-dose on Cycle 2 Day 1 At the beginning of Cycle 1 & Cycle 2 (Each Cycle is 21 days)
Secondary Objective Response Rate (ORR) Evaluation by RECIST 1.1; ORR is defined as the proportion of subjects in the response evaluable population who achieve the best overall response (BOR) of CR or PR Through study completion (an average of one year)
Secondary Disease Control Rate (DCR) DCR is defined as the percentage of response evaluable subjects who achieve a BOR of CR, PR or SD for at least 3 months Through study completion (an average of one year)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03628677 - A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Phase 1
Recruiting NCT05723640 - The Safety and Dosimetry Study of 177Lu-LNC1004 Injection Phase 1
Completed NCT04976803 - Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein
Recruiting NCT04932525 - Gustave Roussy Cancer Profiling Phase 1
Recruiting NCT04643418 - Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04443088 - An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04942717 - Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
Recruiting NCT04169321 - Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors Phase 1
Recruiting NCT05695638 - Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
Completed NCT03318445 - Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair Phase 1
Recruiting NCT04537936 - Psychotherapy Intervention for Latinos With Adv Cancer N/A
Active, not recruiting NCT04577963 - A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06136065 - 68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors Phase 2
Recruiting NCT04015609 - Psychotherapy Intervention for Latinos With Advanced Cancer N/A
Available NCT04100694 - Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor